首页 > 市场调查报告书 > 製药

癌症

免疫肿瘤市场规模、份额和成长分析（按治疗类型、疾病类型、通路和地区划分）－产业预测，2026-2033年

市场调查报告书

商品编码

1897947

免疫肿瘤市场规模、份额和成长分析（按治疗类型、疾病类型、通路和地区划分）－产业预测，2026-2033年

Immuno-Oncology Drugs Market Size, Share, and Growth Analysis, By Treatment Type (Immune Checkpoint Inhibitors, Immune System Modulators), By Disease Type (Melanoma, Lung Cancer), By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，全球免疫肿瘤药物市场规模将达到 272.6 亿美元，到 2025 年将成长至 322.7 亿美元，到 2033 年将成长至 1,246.3 亿美元，预测期（2026-2033 年）的复合年增长率为 18.4%。

免疫肿瘤市场正迅速扩张，因为它提供根据每位患者的基因谱、肿瘤特征和免疫反应量身定制的个人化治疗方案。与传统癌症疗法相比，这种治疗策略不仅提高了存活率并减少了副作用，而且还引入了具有长期缓解潜力的创新治疗选择。免疫肿瘤药物透过特异性靶向癌细胞，保护健康组织，并将损害患者生活品质的有害副作用降至最低。它们利用免疫系统发挥持续抗肿瘤活性的独特能力，改善了患者的整体预后，使免疫肿瘤药物成为癌症治疗领域的变革力量。因此，它们正成为治疗各种癌症的首选方案，并有助于改善长期治疗策略。

推动全球免疫肿瘤药物市场发展的因素

全球免疫肿瘤药物市场的成长主要受监管核准流程的驱动。监管机构的核准至关重要，因为检验了免疫肿瘤疗法的安全性和有效性，使其得以在医疗保健领域销售和使用。这种核准不仅透过证明治疗方法已经过全面测试而让投资者和製药公司放心，而且还刺激了该领域的进一步投资和创新。因此，随着新的免疫肿瘤药物核准，患者将更容易获得先进的疗法，从而促进医疗保健机构的广泛应用，并改善患者的治疗效果。

全球免疫肿瘤药物市场面临的限制因素

限制全球免疫肿瘤药物市场成长的一大主要因素是这些疗法的高昂费用。免疫肿瘤药物的高价可能对病患和医疗服务提供者构成重大障碍，尤其是在医疗资源匮乏的地区。这种经济壁垒可能会限制这些药物的广泛应用，从而阻碍市场扩张。此外，高成本也可能影响保险公司和政府医疗计划将这些疗法纳入医保范围的意愿，从而限制患者获得治疗的机会，进一步阻碍市场成长。

全球免疫肿瘤药物市场趋势

全球免疫肿瘤药物市场的一大趋势是日益重视生物标记的开发和应用。这些生物标记能够帮助肿瘤学家识别具有特定免疫肿瘤疗法良好反应遗传倾向的患者，从而在癌症个体化治疗中发挥关键作用。随着该领域研究的不断深入，生物标记的应用不仅能够优化患者筛选，还能动态监测治疗进展，并根据个别反应及时调整治疗方案。这种向精准医疗的转变旨在优化治疗效果、最大限度地减少副作用，并最终改善癌症患者的治疗结果，因此，生物标记已成为不断发展的免疫肿瘤学领域的重要关注点。

Coloplast Corp（Denmark）
Bristol Myers Squibb Company（US）
Novartis AG（Switzerland）
F. Hoffmann-La Roche Ltd.（Switzerland）
Merck & Co., Inc.（US）
GSK Plc.（UK）
Eli Lilly and Company（US）
Fresenius Kabi AG（Germany）
Pfizer Inc.（US）
AbbVie Inc.（US）
Genentech Inc.（US）
Sanofi（France）
AstraZeneca（UK）
Bayer AG（Germany）
Bluebird Bio, Inc.（US）
Regeneron Pharmaceuticals, Inc.（US）
Amgen Inc.（US）
Johnson & Johnson（US）
Merck KGaA（Germany）
Ipsen（France）

结论与建议

简介目录

Product Code: SQMIG35I2108

Global Immuno-Oncology Drugs Market size was valued at USD 27.26 Billion in 2024 and is poised to grow from USD 32.27 Billion in 2025 to USD 124.63 Billion by 2033, growing at a CAGR of 18.4% during the forecast period (2026-2033).

The market for immuno-oncology drugs is rapidly expanding as they offer a personalized treatment approach tailored to each patient's genetic profile, tumor traits, and immune response. This therapeutic strategy not only leads to increased survival rates and fewer side effects compared to conventional cancer therapies but also introduces innovative treatment options with the potential for long-lasting remission. By specifically targeting cancer cells, immuno-oncology agents preserve healthy tissue, minimizing adverse effects that compromise patients' quality of life. Their unique ability to harness the immune system for sustained anti-tumor activity enhances overall patient outcomes, positioning immuno-oncology drugs as a transformative force in cancer care. Consequently, they are becoming a preferred choice for managing various cancer types while improving long-term management strategies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Immuno-Oncology Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Immuno-Oncology Drugs Market Segments Analysis

Global Immuno-Oncology Drugs Market is segmented by treatment type, disease type, distribution channel and region. Based on treatment type, the market is segmented into immune checkpoint inhibitors, immune system modulators, cancer vaccines, oncolytic virus and others. Based on disease type, the market is segmented into melanoma, lung cancer, blood cancer, renal cell carcinoma, prostate cancer, bladder cancer and others. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Immuno-Oncology Drugs Market

The growth of the global Immuno-Oncology drugs market is significantly fueled by the regulatory approval process for these therapies. Such endorsements from regulatory bodies are essential, as they validate the safety and efficacy of immuno-oncology treatments, allowing them to be marketed and utilized in healthcare settings. This approval not only reassures investors and pharmaceutical companies by demonstrating that the drugs have undergone thorough testing, but also encourages further investment and innovation in this field. Consequently, as new immuno-oncology drugs gain approval, it enhances patient access to advanced treatments, leading to greater adoption among healthcare providers and improved outcomes for patients.

Restraints in the Global Immuno-Oncology Drugs Market

A significant constraint potentially affecting the growth of the global immuno-oncology drugs market is the prohibitive cost associated with these therapies. The high price tag of immuno-oncology drugs can create substantial obstacles for patients and healthcare providers alike, particularly in regions where affordable healthcare is not readily accessible. This financial barrier may restrict the widespread adoption of these drugs, thus hindering market expansion. Furthermore, the elevated costs can influence the readiness of insurance companies and government healthcare programs to include these treatments in their coverage plans, consequently limiting patient access and further impeding market growth.

Market Trends of the Global Immuno-Oncology Drugs Market

A prominent trend in the Global Immuno-Oncology Drugs market is the increasing emphasis on the development and integration of biomarkers. These biological indicators play a crucial role in personalizing cancer treatment by allowing oncologists to identify patients who are genetically predisposed to respond favorably to specific immuno-oncology therapies. As research in this area advances, the use of biomarkers not only enhances patient selection but also facilitates dynamic treatment monitoring, enabling timely adjustments to therapy based on individual responses. This shift towards precision medicine aims to optimize treatment efficacy, minimize adverse effects, and ultimately improve patient outcomes in cancer care, making biomarkers an essential focus in the evolving landscape of immuno-oncology.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Analysis
Case Study Analysis
Patent Analysis

Global Immuno-Oncology Drugs Market Size by Treatment Type & CAGR (2026-2033)

Market Overview
Immune Checkpoint Inhibitors
Immune System Modulators
Cancer Vaccines
Oncolytic Virus
Others

Global Immuno-Oncology Drugs Market Size by Disease Type & CAGR (2026-2033)

Market Overview
Melanoma
Lung Cancer
Blood Cancer
Renal Cell Carcinoma
Prostate Cancer
Bladder Cancer
Others

Global Immuno-Oncology Drugs Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Immuno-Oncology Drugs Market Size & CAGR (2026-2033)

North America (Treatment Type, Disease Type, Distribution Channel)
- US
- Canada
Europe (Treatment Type, Disease Type, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Treatment Type, Disease Type, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Treatment Type, Disease Type, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Treatment Type, Disease Type, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Coloplast Corp (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GSK Plc. (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius Kabi AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genentech Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bluebird Bio, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ipsen (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments